PETACH TIKVAH, ISRAEL and NEW YORK, NY, United States, via eTeligis Inc., 06/10/2014 - - BrainStormCell Therapeutics (OTCQB:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has initiated a study in a mouse model of autism at theFelsensteinMedical Research Center,SacklerFaculty of Medicine, Tel Aviv University, under the direction of Professor DanielOffen. The study will explore the effects of the company's "MSC-NTF" cells on mouse behavior.
The study, which will be conducted using the BTBR mouse model for autism, will investigate repetitive behavior, increased cognitive flexibility and improved sociability in mice after administration of a singleintracerebroventricularinjection of the cells.
Autism is a spectrum of disorders characterized by marked abnormalities in communication and social interactions. Stem cell-based regenerative therapy has been proposed for the treatment of autism, as studies have shown that cell transplantation may affect molecular processes associated with autism pathophysiology. In addition, immune dysfunction has been confirmed with autistic children, and mesenchymal stem cells are known to regulate the immune system. Stem cell research in autism is being conducted at several regenerative medicine research centers including the California Institute of Regenerative Medicine (CIRM).
BrainStormCell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize itsNurOwntechnology through an exclusive, worldwide licensing agreement withRamot, the technology transfer company of Tel Aviv University. For more information, visit the company's website atwww.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStormCell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential",and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated withBrainStorm'slimited operating history, history of losses; minimal working capital, dependence on its license toRamot'stechnology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed inBrainStorm'sannual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance onBrainStorm'sforward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
BrainStormCell Therapeutics Inc.
SOURCE:BrainStormCell Therapeutics, Inc.